本帖最后由 老马 于 2012-1-13 21:20 编辑
$ B4 {' Q1 o2 b4 N* R2 x; l6 w% b7 H9 {! j; j& T
爱必妥和阿瓦斯丁的比较
( O. z! M6 L2 ~
& w1 T$ ^' Z% x- t% V9 |
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 E" ~; r3 L6 ]
1 ~$ E- ~0 F0 A g6 d% T i- t* P
% W5 u( H* v- r7 O+ u! }
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' Y; Z& j9 g7 y/ l4 q
==================================================: ]9 r5 a. T; O* x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 A8 D; S, F% R) w4 [- B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
! Y# M+ u2 {5 L. R& O0 xResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& D" C7 h8 Z9 @. I+ m
|